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Antibodies are a principal determinant of immunity for 
most RNA viruses and have promise to reduce infection 
or disease during major epidemics. The novel coronavirus 
SARS-CoV-2 has caused a global pandemic with millions of 
infections and hundreds of thousands of deaths to date1,2. 
In response, we used a rapid antibody discovery platform to 
isolate hundreds of human monoclonal antibodies (mAbs) 
against the SARS-CoV-2 spike (S) protein. We stratify these 
mAbs into five major classes on the basis of their reactivity 
to subdomains of S protein as well as their cross-reactivity to 
SARS-CoV. Many of these mAbs inhibit infection of authen-
tic SARS-CoV-2 virus, with most neutralizing mAbs recog-
nizing the receptor-binding domain (RBD) of S. This work 
defines sites of vulnerability on SARS-CoV-2 S and dem-
onstrates the speed and robustness of advanced antibody 
discovery platforms.
Human mAbs against the S glycoprotein on the viral sur-
face mediate immunity to other betacoronaviruses including 
SARS-CoV3–7 and Middle East respiratory syndrome coronavi-
rus (MERS-CoV)8–17. Because of this, we and others have hypoth-
esized that human mAbs may have promise for use in prophylaxis, 
post-exposure prophylaxis or treatment of SARS-CoV-2 infection18. 
MAbs can neutralize betacoronaviruses by several mechanisms, 
including blocking attachment of the S protein receptor-binding 
domain (RBD) to a receptor on host cells (which, for SARS-CoV and 
SARS-CoV-2 (ref. 1), is angiotensin-converting enzyme 2 (ACE2))12. 
We hypothesized that the SARS-CoV-2 S protein would induce 
diverse human neutralizing antibodies following natural infec-
tion. While antibody discovery and therapeutic candidate develop-
ment usually takes months to years, there is an urgent need to both 
characterize the human immune response to SARS-CoV-2 infection 
and to develop potential medical countermeasures. Using Zika virus 
as a simulated pandemic pathogen and leveraging recent techno-
logical advances in synthetic genomics and single-cell sequencing, 
we recently isolated hundreds of human mAbs from a single-B-cell 
suspension and tested them in vitro for neutralization and for pro-
tection in small animals and non-human primates, all within 78 d19. 
Using similar methodologies and further efficiency improvements, 
we sought to obtain human mAbs rapidly for SARS-CoV-2 from the 
B cells of some of the first humans identified with the infection in 
North America. We used an approach similar to that in our previous 
technical demonstration with Zika; however, for the SARS-CoV-2 
discovery effort we report here, we used several different workflows 
in parallel (Fig. 1 and Supplementary Table 1), which we completed 
in an expedited time frame (Fig. 1).
We first developed or obtained antigens and recombinant pro-
teins necessary for identifying and isolating antigen-reactive B 
cells. We synthesized a complementary-DNA encoding a stabilized 
trimeric prefusion ectodomain of S protein (S2Pecto)20, expressed 
the protein in 293-F cells, and verified the presence of the prefu-
sion conformation by electron microscopy (Extended Data Fig. 1 
and Supplementary Table 2). We also synthesized and expressed 
the S protein RBD (SRBD) and obtained recombinant S protein 
amino-terminal domain (SNTD) that had been prepared by academic 
or commercial sources. Using these tools, we designed a mAb dis-
covery approach focused on identifying naturally occurring human 
mAbs specific for S.
We obtained informed consent and collected blood samples 
from four patients infected in China who were among the earliest 
identified patients with SARS-CoV-2 infection in North America, 
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Fig. 1 | Workflows and timelines. a, Overview of rapid mAb discovery workflows. The overall scheme is shown, representing the several specific 
workflows conducted in parallel (specified in Supplementary Table 1). Blood was collected and white blood cells were separated, B cells were enriched 
from PBMCs by negative selection using magnetic beads and antigen-specific cells were isolated by flow-cytometric sorting and then were processed 
for direct B cell selection and sequencing or in vitro expansion/activation. Cultured B cells were loaded on a Beacon instrument (Berkeley Lights) for 
functional screening (Extended Data Fig. 3 and Supplementary Video 1) or in a Chromium device (10X Genomics) followed by reverse transcription 
with PCr, sequence analysis, cDNA gene synthesis and cloning into an expression vector and microscale IgG expression in Chinese hamster ovary 
(CHO) cells by transient transfection. recombinant IgG was tested by ELISA for binding to determine antigen reactivity and by a high-throughput 
neutralization screening assay (xCelligence; ACEA) (Extended Data Fig. 4) with authentic virus in a biosafety-level-3 (BSL-3) laboratory for  
functional characterization.
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as well as one healthy donor who served as a negative control 
(Supplementary Table 3). These patients had a history of recent 
laboratory-confirmed SARS-CoV-2 infection acquired in Wuhan or 
Beijing, China. The samples were obtained 35 d (patient 1; the case 
identified in the United States21), 36 d (patient 2) or 50 d (patients 
3 and 4) after the onset of symptoms. We tested plasma or serum 
specimens from the four patients infected with SARS-CoV-2, or 
from a healthy donor (patient 5) as control. Serum/plasma anti-
body ELISA binding assays using S2Pecto, SRBD or SNTD protein from 
SARS-CoV-2 or S2Pecto protein from SARS-CoV revealed that the 
previously infected patients had circulating antibodies that recog-
nized each of the proteins tested, with the highest reactivity against 
the SARS-CoV-2 S2Pecto and SRBD proteins (Fig. 2a). Each of the pre-
viously infected patients also had circulating antibodies that bound 
to SARS-CoV S2Pecto. The serum antibodies from the healthy 
donor did not react with any of the antigens. B cells were enriched 
from peripheral blood mononuclear cells (PBMCs) by negative 
selection using antibody-coated magnetic beads and were stained 
with phenotyping antibodies specific for CD19, IgD and IgM. 
Analytical flow cytometry was performed to assess the frequency 
of antigen-specific memory B cells for each donor. We identified 
class-switched memory B cells by gating for an IgD–IgM−CD19+ 
population (Fig. 2b, and Extended Data Fig. 2). From this memory 
B cell population, we identified antigen-reactive cells using bioti-
nylated recombinant S2Pecto protein or biotinylated RBD fused to 
mouse Fc (RBD–mFc). Patients 1 and 2 had very low frequencies of 
antigen-specific memory B cells that were not greater than twofold 
above the background staining frequency in a non-immune sample 
(from patient 6) (Fig. 2c). In contrast to patients 1 and 2, conva-
lescence in patients 3 and 4 was 2 weeks later, and they exhibited 
0.62% or 1.22% of class-switched B cells that reacted with antigen 
(Fig. 2c). Patients 3 and 4 also exhibited high titers in a 
serum-antibody focus reduction neutralization test (FRNT) 
with an authentic SARS-CoV-2 strain (WA/1/2020) (Fig. 2d). 
Therefore, we focused subsequent efforts on sorting B cells from 
the specimens of patients 3 and 4, which were pooled for efficiency. 
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Fig. 2 | Characterization of SARS-CoV-2 immune donor samples. a, Serum or plasma antibody reactivity for the four SArS-CoV-2 exposed patients and 
one non-immune healthy control, assessed by ELISA using SArS-CoV-2 S2Pecto, SrBD, SNTD, SArS-CoV S2Pecto or PBS. OD450, optical density measurement 
using a microplate reader with a 450-nm filter. b, Gating for memory B cells in total B cells enriched by negative selection using magnetic beads for patient 
4; cells were stained with anti-CD19 antibody conjugated to allophycocyanin (APC) and anti-IgM and anti-IgD antibodies conjugated to fluorescein 
isothiocyanate (FITC). c, Analytical flow cytometric analysis of B cells for patients 1 to 4, compared with that of a healthy individual (patient 6). Plots 
show CD19+IgD–IgM− population using the gating strategy that was used in b. Cells labeled with biotinylated S2Pecto or rBD−mFc antigens were detected 
using phycoerythrin (PE)-conjugated streptavidin. d, Plasma or serum neutralizing activity against the WA1/2020 strain SArS-CoV-2 for patients 1 
to 4 or a healthy donor (patients 6). The percentage neutralization is reported. e, FACS isolation of S2Pecto or rBD–mFc-reactive B cells from pooled 
B cells of patients 3 and 4. Plots show CD19+IgD–IgM− population using gating strategy as in b, and antigen-reactive B cells were identified as in c. f, 
Lymphoblastoid cell line (LCL) supernatant neutralization. Neutralization of the WA1/2020 strain SArS-CoV-2 by supernatant collected from cell cultures 
of S2Pecto- or rBD–mFc-sorted memory B cells that had been stimulated in bulk in vitro on feeder layers expressing CD40L and secreting IL-21 and BAFF. 
The supernatants were tested in a ten-point dilution series in the FrNT, and percentage neutralization is reported. Values shown are the mean ± s.d. of 
technical duplicates.
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Fig. 3 | Reactivity and functional activity of 389 human mAbs. a, Structures of SArS-CoV-2 S antigen. Top, S protein monomer of SArS-CoV-2 
highlighting rBD (blue) and NTD (red) subdomains that were expressed as recombinant proteins. The ACE2-binding site on rBD is shown in orange. 
Known glycans are shown as light gray spheres (PDB 6VYB)37. Middle, The structure of trimeric SArS-CoV-2 spike with one rBD in the ‘head up’ 
conformation. Bottom, Structure (PDB 6M0J)38 of SArS-CoV-2 rBD (blue) and hACE2 (pink), highlighting differences between rBDs of SArS-CoV-2 
and SArS-CoV (cyan). b, mAbs binding to each of four S proteins or subdomains. The figure shows a heatmap for binding of 389 mAbs expressed 
recombinantly, representing OD values collected at 450 nm for each antigen (range, 0.035–4.5). White indicates a lack of detectable binding, while blue 
indicates binding and darker blue indicates higher OD values. c, Screening test for neutralizing activity. Each mAb was tested by rTCA neutralization 
test (Extended Data Figs. 4 and 5) that was based on measurement of rapid cytopathic effect in Vero-furin cells caused by an authentic SArS-CoV-2 
(strain WA1/2020) in a BSL-3 laboratory. Green indicates full protection of cells (full neutralization), purple indicates partial protection of cells (partial 
neutralization) and white indicates that neutralizing activity was not detected. On the basis of both binding and neutralization, we grouped the mAbs 
into classes. Class I mAbs bind to both S2Pecto and SrBD proteins and are SArS-CoV-2-specific. Class II mAbs also bind to both S2Pecto and SrBD proteins 
and cross-react with SArS-CoV. Class III mAbs bind to both S2Pecto and SNTD proteins and are mostly SArS-CoV-2-specific. Class IV mAbs bind only to 
S2Pecto protein and are SArS-CoV-2-specific. Class V mAbs bind only to S2Pecto protein and cross-react with SArS-CoV. d, Heatmap showing usage of 
antibody variable-gene segments for variable (V) and joining (J) genes. Of the 389 antibodies tested in b and c, 324 were found to have unique sequences, 
and those unique sequences were analyzed for genetic features. The frequency counts are derived from the total number of unique sequences with the 
corresponding V and J genes. The V/J frequency counts then were transformed into a Z-score by first subtracting the average frequency, then normalizing 
by the s.d. of the set of antigen-reactive mAbs. red denotes more common gene usage, and blue denotes less common gene usage. e, CDr3 amino  
acid length distribution. The CDr3 of each sequence was determined using PyIr software. The amino acid length of each CDr3 was counted. The 
distribution of CDr3 amino acid lengths for heavy or light chains then was plotted as a histogram and fitted using kernel density estimation for the curves. 
f, Divergence from inferred germline gene sequences. The number of mutations of each mAb relative to the inferred germline variable gene was counted 
for each clone. These numbers then were transformed into percent values and plotted as violin plots. For the heavy chain, values range from 81 to 100, with 
a median of 98, a 25th quartile of 97.3 and a 75th quartile of 99. For the light chain, values range from 87.5 to 100, with a median of 98.6, a 25th quartile of 
97.9 and a 75th quartile of 99.3.
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The pooled memory B cell suspension had frequencies for S2Pecto 
and RBD–mFc that were 0.81% and 0.19% of the IgD–IgM−CD19+ 
population, respectively (Fig. 2e). The bulk sorted S2Pecto- or RBD−
mFc-specific B cells were stimulated on a feeder layer with CD40L, 
interleukin-21 (IL-21) and B cell activating factor (BAFF)22, and 
the secreted antibodies in the resulting cell-culture superna-
tants exhibited neutralizing activity against the WA1/2020 strain 
(Fig. 2f). After 7 d in culture, these activated B cells were removed 
from the feeder layers. Roughly half of these B cells were single-cell 
sequenced using a 10x Chromium single-cell encapsulation auto-
mated system, and antibody genes were synthesized as previously 
described19. The remaining cells were loaded onto a Berkeley 
Lights Beacon optofluidic instrument in a novel medium promot-
ing plasma-cell survival, and antigen reactivity of secreted anti-
bodies from individual B cells was measured for thousands of cells 
(Extended Data Fig. 3). This single-cell analysis showed that ∼55% 
of cultured B cells secreted SP2ecto-reactive IgG (Supplementary 
Video 1). Using the Beacon instrument, we also screened a subset 
of expanded B cells for the ability to block human ACE2 (hACE2) 
receptor binding to the RBD–mFc construct and identified sev-
eral clones secreting mAbs that inhibited RBD–hACE2 interaction 
(Extended Data Fig. 3d). Antigen-reactive B cells were exported 
from the instrument, and the heavy- and light-chain genes from 
single B cells were sequenced and cloned into immunoglobulin 
expression vectors. From 288 total exported cells, we succeeded 
in cloning 78 antigen-reactive mAbs (Supplementary Table 1), 
including two closely related mAbs that blocked hACE2 binding 
to the RBD.
Using the parallel workflows, we isolated 389 recombinant 
SARS-CoV-2-reactive human mAbs that expressed sufficiently well 
as recombinant IgG to characterize the activity of the mAb. The 
recombinant mAbs were tested for binding in ELISA to recombi-
nant monomeric SRBD or SNTD of SARS-CoV-2 or trimeric S2Pecto 
proteins of SARS-CoV-2 or SARS-CoV (Fig. 3a). Neutralizing 
activity of mAbs was assessed using an automated real-time cell 
analysis (RTCA) rapid screening assay19 that allows quantitation 
of cytopathic effect (CPE) with WA1/2020 strain SARS-CoV-2 
in Vero-furin cells (Extended Data Fig. 4). The ELISA and neu-
tralization screening assays revealed that the antibodies could be 
grouped into five binding patterns on the basis of domain recogni-
tion and cross-reactivity (Fig. 3b). There were 178 that mAbs rec-
ognized the RBD domain and 43 that recognized the NTD domain. 
Comparison of binding patterns with full or partial neutralizing 
activity measured by RTCA with SARS-CoV-2 (Fig. 3c) clearly 
showed that most of the neutralizing antibodies (67/70) mapped 
to the RBD, revealing the RBD to be the principal site of vulner-
ability for SARS-CoV-2 neutralization in these patients. Overall, 
49% of the SARS-CoV-2-specific RBD mAbs were neutralizing, 
and 19% of the SARS-CoV cross-reactive mAbs were neutralizing. 
We then used the RTCA assay to rank mAbs by their neutralizing 
potency (Extended Data Fig. 5) and identified several mAbs with 
half-maximal inhibitory concentration (IC50) values below 100 ng 
ml–1. We examined the sequences for the 389 antibodies to assess 
the diversity of antigen-specific B cell clonotypes discovered. The 
analysis showed that among the 389 mAbs, 321 unique amino acid 
sequences were present and 313 unique Vh–Jh–CDRH3–Vl–Jl–
CDRL3 clonotypes were represented, with diverse usage of antibody 
variable genes (Fig. 3d and Supplementary Table 4). The length dis-
tributions of CDR3 amino acids in the heavy and light chains were 
typical of human repertoires (Fig. 3e)23. The high relatedness of 
sequences to the inferred germline variable genes observed for this 
panel of antibodies (Fig. 3f) contrasts with the much higher levels 
of somatic mutation seen in B cell recall responses against common 
human pathogens such as influenza24. These data suggest that the 
SARS-CoV-2 antibodies were likely induced during the primary 
response to SARS-CoV-2 infection and not by a recall response to a 
distantly related seasonal coronavirus. We next performed neutral-
ization assays with a recombinant vesicular stomatitis virus (VSV) 
expressing SARS-CoV-2 S (VSV-SARS-CoV-2)25 that confirmed 
neutralizing activity of 49 mAbs identified as neutralizing by the 
rapid RTCA screening assay (Extended Data Fig. 6). We also con-
firmed high neutralizing potency for representative potent mAbs in a 
quantitative conventional neutralization assay using a SARS-CoV-2 
luciferase reporter virus (Fig. 4a). In addition, we tested SARS-CoV 
S2Pecto cross-reactive mAbs for cross-neutralization of a SARS-CoV 
luciferase reporter virus (Fig. 4b), which revealed relatively weak 
neutralization of heterologous SARS-CoV. Together, these results 
confirmed that mAbs recognizing multiple epitopes on S were able 
to neutralize SARS-CoV-2 and cross-react with SARS-CoV, with 
most neutralizing mAbs specific for the RBD of S.
Since the emergence of SARS-CoV-2, several groups have 
reported the isolation of neutralizing antibodies from survivors that 
target the S protein26–33. There are similarities between our approaches 
and those of others, for example employing antigen-specific enrich-
ment with both RBD26,27,29,30,32 and full-length S trimer26,28,33 as well 
as the use of single-cell sequencing and gene synthesis29. A com-
mon finding across these studies is that the SARS-CoV-2 RBD is the 
target of potent neutralizing antibodies. In this work, we coupled 
single-B-cell antibody gene sequencing with high-throughput IgG 
isolation and screening assays to isolate and profile a large num-
ber of neutralizing mAbs in a period of only weeks after sample 
acquisition. The technological advances of our workflow included 
rapid antigen binding and functional (hACE2 blocking) screens 
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Fig. 4 | Neutralizing activity of potent mAbs against SARS-CoV-2 and 
SARS-CoV. a, Dose–response neutralization of SArS-CoV-2 luciferase 
reporter virus by representative potently neutralizing mAbs that were 
identified by rapid rTCA screening assay. IC50 values are indicated for each 
mAb. Data shown are the mean of two technical replicates from one of two 
independent experiments, and error bars denote the s.d. for each point. 
b, Neutralization of SArS-CoV luciferase reporter virus by cross-reactive 
mAbs COV2-2678 and COV2-2514. IC50 values are indicated for each mAb, 
with the ‘–’ symbol indicating that mAbs that did not neutralize SArS-CoV. 
Data shown are the mean ± s.d. of two technical replicates from one of two 
independent experiments.
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to thousands) screening of mAbs for neutralization of authentic 
SARS-CoV-2 virus to rapidly identify the leads. In our particu-
lar example, sequences of confirmed neutralizing antibodies were 
transferred to downstream manufacturing partners only 18 d after 
antigen-specific cell sorting. However, given the need for affinity 
maturation and the development of a mature B cell response, there 
are limits on the timeline from infection to isolation of potent neu-
tralizing antibodies with therapeutic promise. It has been previously 
shown for Ebola virus infection that potently neutralizing antibod-
ies are not easily isolated from memory B cells until later timepoints 
in the first year after infection34,35. It is possible that our success in 
identifying antigen-specific B cells from patients 3 and 4 here at 50 
d after onset, but not from patients 1 and 2 at 35 or 36 d after onset, 
reflected additional maturation of the memory B cell response that 
occurred in the additional 2 weeks of convalescence, although we 
note that others have isolated neutralizing mAbs from individuals 
approximately 30 d after infection27. Overall, our work illustrates the 
promise of integrating recent technological advances for antibody 
discovery and helps to define the RBD of SARS-CoV-2 S as a major 
site of vulnerability for vaccine design and therapeutic-antibody 
development. The most potent neutralizing human mAbs isolated 
here also could serve as candidate biologics to prevent or treat 
SARS-CoV-2 infection36.
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Methods
Research participants. We studied four patients in North America with recent 
laboratory-confirmed symptomatic SARS-CoV-2 infections that were acquired 
in China (Supplementary Table 3). The studies were approved by the Institutional 
Review Board of Vanderbilt University Medical Center, and subsite studies were 
approved by the Institutional Review Board of the University of Washington or 
the Research Ethics Board of the University of Toronto. Samples were obtained 
after written informed consent. Patient 1 (35-year-old male) was the earliest 
reported case of SARS-CoV-2 infection in the United States, who presented 
with disease in Seattle, Washington, on 19 January 2020 (ref. 21), a blood sample 
was obtained for study on 19 February 2020. Patient 2 (52-year-old female) was 
infected following close exposure in Beijing, China, to an infected person from 
Wuhan, China, during the period between 23 January 2020 to 29 January 2020. 
She presented with mild respiratory disease symptoms from 1 February 2020 to 
4 February 2020 that occurred after travel to Madison, Wisconsin. She obtained 
a diagnosis of infection by testing at the US Centers for Disease Control on 5 
February 2020. Blood samples were obtained for study on 7 March 2020 and 8 
March 2020. Patient 3 (a 56-year-old male) and patient 4 (a 56-year-old female) 
are a married couple and residents of Wuhan, China, who traveled to Toronto, 
Canada, on 22 January 2020. Patient 3 first developed a cough without fever 
on 20 January 2020 in the city of Wuhan, where he had a normal chest X-ray 
on that day. He flew to Canada with persisting cough and arrived in Canada 
on 22 January 2020, where he became febrile. He presented to a hospital in 
Toronto, 23 January 2020 complaining of fever, cough and shortness of breath; 
a nasopharyngeal swab was positive by PCR testing for SARS-CoV-2. His chest 
X-ray at that time was abnormal, and he was admitted for non-intensive-care-unit 
impatient care. He improved gradually with supportive care, was discharged  
30 January 2020 and rapidly became asymptomatic except for a residual dry 
cough that persisted for a month. He had a negative nasopharyngeal swab PCR 
test on 19 February 2020. Patient 4 is the wife of patient 3 who traveled with her 
husband from Wuhan. She was never symptomatic with respiratory symptoms 
or fever but was tested because of her exposure. Her nasopharyngeal swab was 
positive for SARS-CoV-2 by PCR, on 24 January 2020; repeat testing in follow-up 
on 21 February 2020 was negative. PBMCs were obtained by leukapheresis from 
patients 3 and 4 on 10 March 2020, which was 50 d since symptom onset of 
patient 3. Samples were transferred to Vanderbilt University Medical Center in 
Nashville, Tennessee, on 14 March 2020.
Cell culture. Vero E6 (CRL-1586, American Type Culture (ATCC)), Vero CCL81 
(CCL-81, ATCC) and HEK293T (CRL-3216 ATCC) were maintained at 37 °C in 
5% CO2 in DMEM containing 10% (vol/vol) heat-inactivated FBS, 10 mM HEPES 
pH 7.3, 1 mM sodium pyruvate, 1× non-essential amino acids, and 100 U ml–1 of 
penicillin–streptomycin. Vero-furin cells were obtained from T. Pierson (NIH) and 
have been described previously39. Expi293F cells (Thermo Fisher Scientific, A1452) 
were maintained at 37 °C in 8% CO2 in Expi293F Expression Medium (Thermo 
Fisher Scientific, A1435102). ExpiCHO cells (Thermo Fisher Scientific, A29127) 
were maintained at 37 °C in 8% CO2 in ExpiCHO Expression Medium (Thermo 
Fisher Scientific, A2910002). Mycoplasma testing of Expi293F and ExpiCHO 
cultures was performed on a monthly basis using a PCR-based mycoplasma 
detection kit (ATCC, 30-1012K).
Viruses. SARS-CoV-2 strain 2019 n-CoV/USA_WA1/2020 was obtained from 
the Centers for Disease Control and Prevention (a gift from N. Thornburg). Virus 
was passaged in Vero CCL81 cells and titrated by plaque assay on Vero E6 cells. 
All work with infectious SARS-CoV-2 was approved by the Washington University 
School of Medicine or UNC-Chapel Hill Institutional Biosafety Committees and 
conducted in approved BSL-3 facilities using appropriate powered air-purifying 
respirators and personal protective equipment.
Recombinant antigens and proteins. A gene encoding the ectodomain of 
a prefusion conformation-stabilized SARS-CoV-2 S (S2Pecto) protein was 
synthesized and cloned into a DNA plasmid expression vector for mammalian 
cells. A similarly designed S protein antigen with two prolines and removal of 
the furin cleavage site for stabilization of the prefusion form of S was reported 
previously20. Briefly, this gene includes the ectodomain of SARS-CoV-2 (to residue 
1,208), a T4 fibritin trimerization domain, an AviTag site-specific biotinylation 
sequence, and a carboxy-terminal 8×-histidine tag. To stabilize the construct in 
the prefusion conformation, we included substitutions K986P and V987P and 
mutated the furin cleavage site at residues 682–685 from RRAR to ASVG. This 
recombinant spike 2P-stabilized protein (designated here as S2Pecto) was isolated 
by metal affinity chromatography on HisTrap Excel columns (GE Healthcare), 
and protein preparations were purified further by size-exclusion chromatography 
on a Superose 6 Increase 10/300 column (GE Healthcare). The presence of 
trimeric, prefusion conformation S protein was verified by negative-stain electron 
microscopy (Extended Data Fig. 1 and Supplementary Table 2). To express the 
SRBD subdomain of SARS-CoV-2 S protein, residues 319–541 were cloned into a 
mammalian expression vector downstream of an IL-2 signal peptide and upstream 
of a thrombin cleavage site, an AviTag, and a 6×-His tag. RBD–mFc was purchased 
from Sino Biological (40592-V05H). For B cell labeling and sorting, RBD–mFc and 
S2Pecto proteins were biotinylated using the EZ-Link Sulfo-NHS-LC-Biotinylation 
Kit and vendor’s protocol (Thermo Fisher Scientific, 21435).
Electron microscopy stain grid preparation and imaging of SARS-CoV-2 
S2Pecto protein. For screening and imaging of negatively stained SARS-CoV-2 
S2Pecto protein, approximately 3 µL of the sample at concentrations of about 10 
to 15 µg/mL was applied to a glow discharged grid with continuous carbon film 
on 400 square mesh copper EM grids (Electron Microscopy Sciences). The grids 
were stained with 0.75% uranyl formate (UF)40. Images were recorded on a Gatan 
US4000 4k × 4k CCD camera using an FEI TF20 (TFS) transmission electron 
microscope operated at 200 keV and control with SerialEM41. All images were 
taken at ×50,000 magnification with a pixel size of 2.18 Å pix–1 in low-dose mode 
at a defocus of 1.5–1.8 μm. The total dose for the micrographs was ~25 e− per Å2. 
Image processing was performed using the cryoSPARC software package42. Images 
were imported, and CTF estimation was done for the particles. The images then 
were denoised and picked with Topaz43. The particles were extracted with a box 
size of 256 pixels and binned to 128 pixels. Two-dimensional class averages were 
performed (see Supplementary Table 2 for details).
Patient selection and target-specific memory B cells isolation. B cell responses 
to SARS-CoV-2 in PBMCs from a cohort of four patients with documented 
previous infection with the virus were analyzed for antigen specificity, and 
PBMCs were used for SARS-CoV-2-specific B cell enrichment. The frequency of 
SARS-CoV-2 S protein-specific B cells was identified by antigen-specific staining 
with either biotinylated S2Pecto or RBD–mFc protein. Briefly, B cells were purified 
magnetically (STEMCELL Technologies) and stained with anti-CD19–APC 
(BioLegend clone HIB19 cat. no. 982406, lot B270238, 1:10 dilution), anti-IgD–
FITC (BioLegend clone IA6–2, cat. no. 348206, lot B258195, 1:20 dilution), and 
anti-IgM–FITC (BioLegend clone MHM-88, cat. no. 314506, lot B218736, 1:20 
dilution) phenotyping antibodies and biotinylated antigen. A DAPI stain was 
used as a viability dye to distinguish dead cells. Antigen-labeled class-switched 
memory B cell–antigen complexes (CD19+IgM–IgD−Ag+DAPI−) were detected 
with a R-PE-labeled streptavidin conjugate (Thermo Fisher Scientific, S866, 1:500 
dilution). After identification of the two patients with the highest B cell response 
against SARS-CoV-2 (patients 3 and 4), target-specific memory B cells were 
isolated by flow-cytometric sorting using an SH800 cell sorter (Sony) from pooled 
PBMCs of these two patients, after labeling of B cells with either biotinylated 
S2Pecto or RBD–mFc proteins. Flow-cytometric data were analyzed with the SH800 
software and FlowJo version 10 (Tree Star).
Overall, from >4 ×108 PBMCs, 2,126 RBD–mFc-reactive and 5,544 
S2Pecto-reactive B cells were sorted and subjected to further analysis. Several 
methods were implemented for the preparation of sorted B cells for sequencing. 
Approximately 4,500 sorted cells were subjected to direct sequencing immediately 
after flow cytometric sorting. The remaining cells were expanded in culture 
for 8 d in the presence of irradiated 3T3 feeder cells that were engineered to 
express human CD40L, IL-21 and BAFF, as described previously22. The expanded 
lymphoblastoid cell lines (LCLs) secreted high levels of S-protein-specific 
antibodies, as confirmed by ELISA, to detect antigen-specific human antibodies in 
culture supernatants. Approximately 40,000 expanded LCLs were sequenced using 
the Chromium sequencing method (10x Genomics).
Microfluidic device selection of single antigen-specific B cells. Activated 
memory B cells were screened using Berkeley Lights’ Beacon optofluidic 
system. Purified B cell samples were imported automatically onto OptoSelect 
11k chips in a novel plasmablast survival medium that promotes antibody 
secretion and preserves cell viability44. Single-cell penning was then performed 
using OEP technology, in which light is used to transfer B cells into individual 
nanoliter-volume chambers (NanoPens). Using this light-based manipulation, 
thousands of LCLs were transferred into pens across multiple chips in each 
workflow. We performed an on-chip, fluorescence-based assay to identify 
antibodies that bound SARS-CoV-2 S2Pecto or RBD–mFc protein. We prepared 
6- to 8-µm and 10- to 14-µm RBD–mFc-conjugated beads by coupling biotinylated 
RBD–mFc protein to streptavidin-coated polystyrene particles (Spherotech). We 
prepared 6- to 8-µm S2Pecto protein-conjugated beads by coupling full-length 
S2Pecto protein to streptavidin-coated polystyrene particles. Assays consisted of 
mixing beads conjugated with the RBD–mFc or S2Pecto proteins with Alexa Fluor 
(AF)-labeled anti-human secondary antibodies (Thermo Fisher Scientific cat. no. 
A-21090) at a 1:100 dilution and importing this assay mixture into OptoSelect 
11k chips. Antigen-specific antibodies bound the antigen-conjugated beads, 
which then sequestered the fluorescent secondary antibody. Cells secreting 
antigen-specific antibodies were identified by locating the NanoPens immediately 
adjacent to the fluorescent beads. We also performed an on-chip assay to select 
antibodies that blocked the interaction of hACE2 and the RBD of SARS-CoV-2. 
The blocking assay was performed by first co-incubating LCLs and 10- to 14-µm 
RBD–mFc-conjugated streptavidin-coated beads (Spherotech) in the NanoPen 
chambers to allow for secreted antibodies to saturate the antigen. Then, a mixture 
of recombinant hACE2 with a FLAG tag (Sigma-Aldrich cat. no. SAE0064), a rat 
anti-FLAG AF 647 antibody at a 1:50 dilution (BioLegend clone L5, cat. no. 637315, 
Lot B265929) and an anti-human IgG AF 568 antibody at a 1:100 dilution (Thermo 
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Fisher Scientific cat. no. A-21090) was perfused through the OptoSelect 11k chip 
and allowed to diffuse into the NanoPen chambers. RBD-binding antibodies were 
identified by locating pens with RBD–mFc-conjugated beads that were fluorescent 
when imaged using the Beacon TRED filter cube. Simultaneously, hACE2 binding 
to the RBD-coated beads was detected using a Cy5 filter cube. NanoPen chambers 
containing RBD–mFc-conjugated beads with fluorescence in both filter cubes were 
classified as containing B cells secreting anti-SARS-CoV-2 antibodies that bound 
RBD but that did not demonstrate hACE2-blocking activity. NanoPen chambers 
that contained RBD–mFc-conjugated beads that were fluorescent in the TRED 
channel but non-fluorescent in the Cy5 channel contained secreted antibodies that 
had both bound RBD and blocked hACE2–RBD interaction. Antigen-specific cells 
of interest were exported from specific NanoPen chambers to individual wells of 
96-well reverse transcription–PCR plates containing lysis buffer.
Sequencing and cloning of single antigen-specific B cells. After export from 
the Beacon instrument, antibody heavy- and light-chain sequences for B cells 
secreting RBD–mFc- or S2Pecto-binding antibodies were amplified and recovered 
using components of the Opto Plasma B Discovery cDNA Synthesis Kit (Berkeley 
Lights). Antibody heavy- and light-chain sequences were amplified through a 
5′ RACE approach using the kit’s included ‘BCR Primer 2’ forward primer and 
isotype-specific reverse primers. The 5′-RACE-amplified cDNA was sequenced 
using the Pacific Biosciences Sequel platform using the SMRTbell Barcoded 
Adapt Complete Prep-96 kit (Pacific Biosciences) and a 6-h movie time. In a 
redundant sequencing approach, heavy- and light-chain sequences were amplified 
using a cocktail of custom V- and J-gene-specific primers (similar to previously 
described human Ig gene-specific primers45) from the original 5′-RACE-amplified 
cDNA while the products of the gene-specific amplification were sent for Sanger 
sequencing (GENEWIZ). The sequences generated by these two approaches were 
analyzed using our Python-based antibody variable-gene analysis tool (PyIR; 
https://github.com/crowelab/PyIR)46 to identify which V and J genes most closely 
matched the nucleotide sequence. Heavy- and light-chain sequences were then 
amplified from the original cDNA using cherry-picked V- and J-gene-specific 
primers most closely corresponding to the V and J gene calls made by PyIR. These 
primers include adapter sequences which allow Gibson-based cloning into a 
monocistronic IgG1 expression vector (pMCis_G1). Similar to a vector described 
below, this vector contains an enhanced 2A sequence and GSG linker that allows 
simultaneous expression of mAb heavy and light chain genes from a single 
construct upon transfection47. The pMCis_G1 vector was digested using the New 
England BioLabs restriction enzyme FspI, and the amplified paired heavy- and 
light-chain sequences were cloned through Gibson assembly using NEBuilder HiFi 
DNA Assembly Master Mix. After recovered sequences were cloned into pMCis_
G1 expression constructs, recombinant antibodies were expressed in CHO cells 
and were purified by affinity chromatography as detailed below. Antigen-binding 
activity was confirmed using plate-based ELISA.
Generation of antibody variable-gene libraries from single B cells. As an 
alternative approach, we also used a second major approach for isolation of 
SARS-CoV-2-reactive antibodies. In some experiments, the Chromium Single 
Cell V(D)J workflow with B-cell-only enrichment option was used for generating 
linked heavy-chain and light-chain antibody profiling libraries. Approximately 
2,866 directly sorted S2Pecto or 1,626 RBD–mFc protein-specific B cells were split 
evenly into 2 replicates each and separately added to 50 μl of RT Reagent Mix, 
5.9 μl of Poly-dt RT Primer, 2.4 μl of Additive A and 10 μl of RT Enzyme Mix B to 
complete the Reaction Mix as per the vendor’s protocol, which then was loaded 
directly onto a Chromium chip (10x Genomics). Similarly, for the remaining 
sorted cells that were expanded in bulk, approximately 40,000 cells from 2 separate 
sorting approaches were split evenly across 4 reactions and processed separately 
as described above, before loading onto a Chromium chip. The libraries were 
prepared following the User Guide for Chromium Single Cell V(D)J Reagents kits 
(CG000086_REV K).
Next-generation DNA sequence analysis of antibody variable genes. Chromium 
Single Cell V(D)J B-Cell-enriched libraries were quantified, normalized and 
sequenced according to the User Guide for Chromium Single Cell V(D)J Reagents 
kits (CG000086_REV C). The two enriched libraries from direct flow cytometric 
cell sorting were sequenced on a NovaSeq sequencer (Illumina) with a NovaSeq 
6000 S1 Reagent Kit (300 cycles) (Illumina). The four enriched libraries from 
bulk expansion were sequenced on a NovaSeq sequencer with a NovaSeq 6000 S4 
Reagent Kit (300 cycles) (Illumina). All enriched V(D)J libraries were targeted for 
sequencing depth of at least 5,000 raw read pairs per cell.
Bioinformatics analysis of single-cell sequencing data. Following sequencing, 
all samples were demultiplexed and processed through the 10x Genomics Cell 
Ranger software (version 2.1.1). The down-selection to identify lead candidates 
for expression was carried out in two phases. In the first phase, all paired antibody 
heavy- and light-chain variable-gene cDNA nucleotide sequences obtained that 
contained a single heavy- and light-chain sequence were processed using PyIR. We 
considered heavy- and light-chain-encoding gene pairs productive and retained 
them for additional downstream processing if they met the following criteria: (1) 
did not contain a stop codon, (2) encoded an intact CDR3 and (3) contained an 
in-frame junctional region. The second phase of processing eliminated redundant 
sequences (those with identical amino acid sequences). Any antibody variant that 
was designated as an IgM isotype (based on the sequence and assignment using 
the 10x Genomics Cell Ranger V(D)J software, version 2.1.1) was removed from 
consideration (while IgG and IgA isotype antibodies were retained). The identities 
of antibody variable-gene segments, CDRs and mutations from inferred germline 
gene segments were determined by using PyIR.
Antibody gene synthesis. Sequences of selected mAbs were synthesized using 
a rapid high-throughput cDNA synthesis platform (Twist Bioscience) and 
subsequently cloned into an IgG1 monocistronic expression vector (designated as 
pTwist-mCis_G1) for mammalian cell culture mAb secretion. This vector contains 
an enhanced 2A sequence and GSG linker that allows simultaneous expression of 
mAb heavy- and light-chain genes from a single construct upon transfection47.
MAb production and purification. For high-throughput production of 
recombinant mAbs, we adopted approaches designated as ‘micro-scale’ or 
‘midi-scale’. For ‘micro-scale’ mAbs expression, we performed micro-scale 
transfection (~1 ml per antibody) of CHO cell cultures using the Gibco ExpiCHO 
Expression System and a protocol for deep 96-well blocks (Thermo Fisher Scientific), 
as previously described19. Briefly, synthesized antibody-encoding lyophilized DNA 
was reconstituted in OptiPro serum-free medium (OptiPro SFM) and used for 
transfection of ExpiCHO cell cultures into 96-deep-well blocks. For high-throughput 
micro-scale mAb purification, clarified culture supernatants were incubated with 
MabSelect SuRe resin (Cytiva), washed with PBS, eluted, buffer-exchanged into 
PBS using Zeba Spin Desalting Plates (Thermo Fisher Scientific) and stored at 4 °C 
until use. For ‘midi-scale’ mAbs expression, we performed transfection (~15 ml 
per antibody) of CHO cell cultures using the Gibco ExpiCHO Expression System 
and protocol for 50 ml mini bioreactor tubes (Corning), as described by the 
vendor. For high-throughput midi-scale mAb purification, culture supernatants 
were purified using HiTrap MabSelect SuRe (Cytiva) on a 24-column parallel 
protein chromatography system (Protein BioSolutions). Purified mAbs were 
buffer-exchanged into PBS, concentrated using Amicon Ultra-4 50 KDa Centrifugal 
Filter Units (Millipore Sigma) and stored at 4 °C until use.
ELISA binding screening assays. Wells of 96-well microtiter plates were coated 
with purified recombinant SARS-CoV-2 S protein, SARS-CoV-2 SRBD protein, 
SARS-CoV-2 SNTD (kindly provided by P. McTamney, K. Ren and A. Barnes, 
Astra Zeneca) or SARS-CoV S protein (kindly provided by S. Bangaru and A. 
Ward, Scripps Research Institute) at 4 °C overnight. Plates were blocked with 2% 
non-fat dry milk and 2% normal goat serum in DPBS containing 0.05% Tween-20 
(DPBS-T) for 1 h. For mAb screening assays, Supernatants from CHO cell culture 
or purified mAbs were diluted 1:20 in blocking buffer, added to the wells and 
incubated for 1 h at ambient temperature. The bound antibodies were detected 
using goat anti-human IgG conjugated with horseradish peroxidase (Southern 
Biotech) and TMB substrate (Thermo Fisher Scientific). Color development 
was monitored, 1N hydrochloric acid was added to stop the reaction and the 
absorbance was measured at 450 nm using a spectrophotometer (Biotek).
RTCA. To screen for neutralizing activity in the panel of recombinantly expressed 
mAbs, we used a high-throughput and quantitative RTCA assay and xCelligence 
RTCA HT Analyzer (ACEA Biosciences) that assesses kinetic changes in cell 
physiology, including virus-induced cytopathic effect (CPE). Twenty µl of cell 
culture medium (DMEM supplemented with 2% FBS) was added to each well 
of a 384-well E-plate using a ViaFlo384 liquid handler (Integra Biosciences) to 
obtain background reading. Six thousand (6,000) Vero-furin cells in 20 μl of cell 
culture medium were seeded per well, and the plate was placed on the analyzer. 
Sensograms were visualized using RTCA HT software version 1.0.1 (ACEA 
Biosciences). For a screening neutralization assay, equal amounts of virus were 
mixed with micro-scale purified antibodies in a total volume of 40 μ using DMEM 
supplemented with 2% FBS as a diluent and incubated for 1 h at 37 °C in 5% CO2. 
At ∼17–20 h after seeding the cells, the virus–mAb mixtures were added to the 
cells in 384-well E-plates. Wells containing virus only (in the absence of mAb) and 
wells containing only Vero cells in medium were included as controls. Plates were 
measured every 8–12 h for 48–72 h to assess virus neutralization. Micro-scale 
antibodies were assessed in four 5-fold dilutions (starting from a 1:20 sample 
dilution), and their concentrations were not normalized. In some experiments, 
mAbs were tested in triplicate using a single (1:20) dilution. Neutralization was 
calculated as the percent of maximal cell index in control wells without virus 
minus cell index in control (virus-only) wells that exhibited maximal CPE at 
40–48 h after applying virus–antibody mixture to the cells. A mAb was classified 
as fully neutralizing if it completely inhibited SARS-CoV-2-induced CPE at the 
highest tested concentration, while a mAb was classified as partially neutralizing 
if it delayed but did not fully prevent CPE at the highest tested concentration. 
Representative sensograms for fully neutralizing and partially neutralizing mAbs 
are shown in Extended Data Fig. 4. For mAb potency ranking experiments, 
individual mAbs identified as fully neutralizing from the screening study were 
assessed by FRNT.
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Sequence analysis of antigen-reactive mAb sequences. Sequences of the 389 
mAbs isolated by different approaches were combined and run through PyIR to 
identity the V genes, J genes, CDR3 lengths and percent identity to germline, and 
sequence within the FR1–FR4 region for both heavy and light chains. Sequences 
were then deduplicated on the nucleotide sequences identified in the FR1–FR4 
region. Among the 389 mAbs, there were 324 unique nucleotide sequences  
(321 unique amino acid sequences) that were analyzed for V/D/J gene usage,  
CDR3 length and somatic mutation. First, the number of sequences with 
corresponding V and J genes were counted. The V/J frequency counts were then 
transformed into a Z-score by first subtracting away the average frequency then 
normalizing by the s.d. of the total set of antigen-reactive mAbs. The Z-score was 
then plotted as a heatmap using python seaborn library. The amino acid length of 
each CDR3 was counted. The distribution of CDR3 amino acid lengths were then 
plotted as histograms and fitted using kernel density estimation for the curves 
using python seaborn library. The number of mutations for each mAb relative to 
the inferred germline variable-gene sequence was counted for each chain. This 
number was then transformed into a percentage value. These values were then 
plotted as a categorical distribution plot as a violin plot using the python seaborn.
catplot library.
FRNT. Serial dilutions of serum or plasma were incubated with 102 FFU of 
SARS-CoV-2 for 1 h at 37 °C. The serum–virus or plasma–virus mixtures were then 
added to Vero E6 cell monolayers in 96-well plates for 1 h at 37 °C. Subsequently, 
cells were overlaid with 1% (wt/vol) methylcellulose in Minimum Essential 
Medium (MEM) supplemented to contain 2% heat-inactivated FBS. Plates were 
fixed 30 h later by removing overlays and were fixed with 4% PFA in PBS for 
20 min at room temperature. The plates were incubated sequentially with 1 µg ml–1 
rCR3022 anti-S antibody5 and a goat anti-human IgG (γ-chain specific)-peroxidase 
antibody (Sigma-Aldrich, cat. no. A6029) in PBS supplemented with 0.1% (wt/vol) 
saponin (Sigma) and 0.1% BSA. SARS-CoV-2-infected cell foci were visualized 
using TrueBlue peroxidase substrate (KPL) and quantitated on an ImmunoSpot 
5.0.37 Macro Analyzer (Cellular Technologies).
SARS-CoV or SARS-CoV-2 neutralization assays using SARS-CoV or 
SARS-CoV-2 luciferase reporter viruses. Full-length viruses expressing luciferase 
were designed and recovered via reverse genetics as described previously48,49. 
Viruses were titered in Vero E6 cell culture monolayers to obtain a relative light 
units (RLU) signal of at least 20× the cell-only control background. Vero E6 cells 
were plated at 20,000 cells per well the day prior in clear-bottom black-walled 
96-well plates (Corning no. 3904). Neutralizing antibodies were diluted serially 
by fourfold for up to eight dilutions. SARS-Urbani NanoLuc or SARS-CoV-2 
NanoLuc virus were mixed with serially diluted antibodies. Antibody–virus 
complexes were incubated at 37 °C in 5% CO2 for 1 h. Following incubation, 
growth medium was removed, and virus–antibody dilution complexes were added 
to the cells in duplicate. Virus-only and cell-only controls were included in each 
neutralization-assay plate. Following infection, plates were incubated at 37 °C in 
5% CO2 for 48 h. After the 48-h incubation, cells were lysed and luciferase activity 
was measured using the Nano-Glo Luciferase Assay System (Promega), according 
to the manufacturer’s specifications.
Neutralization assays using a recombinant VSV-SARS-CoV-2 virus. 
Neutralization assays using replication-competent VSV expressing enhanced green 
fluorescent protein (eGFP) and the SARS-CoV-2 S protein with a C-terminal 
deletion were performed, as previously described25. Briefly, indicated dilutions of 
mAbs were incubated with VSV-SARS-CoV-2 for 1 h at 37 °C. Antibody–virus 
complexes then were added to Vero E6 cells in 96-well plates and incubated 
at 37 °C for 7.5 h. Cells were fixed at room temperature in 2% formaldehyde 
containing 10 µg ml–1 Hoechst 33342 nuclear stain for 45 min. Fixative was replaced 
with PBS prior to imaging. Images were acquired using an InCell 2000 Analyzer 
automated microscope (GE Healthcare) in both the DAPI and FITC channels to 
visualize nuclei and infected cells (×4 objective, 4 fields per well). Images were 
analyzed using the Multi Target Analysis Module of the InCell Analyzer 1000 
Workstation Software (GE Healthcare). GFP-positive cells were identified using the 
top hat segmentation method and counted within the InCell Workstation software. 
Neutralization assay data are summarized in Extended Data Fig. 6.
High-throughput mAb quantification. High-throughput quantification of 
micro-scale-produced mAbs was performed from CHO culture supernatants or 
micro-scale purified mAbs in a 96-well plate format using the Cy-Clone Plus Kit 
and an iQue Plus Screener flow cytometer (IntelliCyt Corp), according to the 
vendor’s protocol. Purified mAbs were assessed at a single dilution (1:10 final, 
using 2 μl of purified mAb per reaction), and a control human IgG solution with 
known concentration was used to generate a calibration curve. Data were analyzed 
using ForeCyt software version 6.2 (IntelliCyt Corp).
Quantification and statistical analysis. The descriptive statistics mean ± SEM 
or mean ± SD were determined for continuous variables as noted. Technical and 
biological replicates are described in the figure legends. Statistical analyses were 
performed using Prism v8.0 (GraphPad).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The main data supporting the results in this study are available within the paper 
and Supplementary Information. The ImMunoGeneTics database is available from 
http://www.imgt.org/. The analysis pipeline PyIR (https://github.com/crowelab/
PyIR) and the specific scripts used for sequence analysis (https://github.com/
crowelab/cov2-panel-scripts) are available. Structures deposited by other groups 
for the full-length spike trimer (6VYB) and the RBD–hACE2 complex (6M0J) 
that were used for visualization in this paper are publicly available (www.rcsb.
org). Sequences for mAbs described in this study have been deposited at GenBank 
and are available under the following accession codes: MT665032–MT665070, 
MT665419–MT665457, MT665071–MT665418 and MT665458–MT665805. 
Datasets are available from the corresponding authors upon reasonable request.
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Extended Data Fig. 1 | Expression and validation of prefusion-stabilized SARS-CoV-2 S2Pecto protein. a. reducing SDS-PAGE gel indicating S2Pecto protein 
migrating at approximately 180 KDa. One representative protein preparation is shown. b. representative micrograph of negative-stain electron microscopy 
with S2Pecto protein preparation. Scale bar denotes 100 nm. c. 2D class-averages of S2Pecto protein in the prefusion conformation. The size for each box is 
128 pixels. Detailed information on image collection is available in Supplementary Table 2.
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Extended Data Fig. 2 | Representative gating strategy for antigen-specific cell sorting. representative gating strategy for profiling of antigen-specific B 
cell frequency for donors. Subject 4 is shown, and phenotypic markers are shown on plot axes. Arrows indicate cell populations derived from gates.
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Extended Data Fig. 3 | Functional assays from single antigen-reactive B cells. a. Biotinylated antigen (dark grey) was coupled to a streptavidin-conjugated 
polystyrene bead (light grey). Antibodies (blue) are secreted by single B cells loaded into individual NanoPens on the Berkeley Lights Beacon optofluidic 
device. Antibody binding to antigen was detected with a fluorescent anti-human IgG secondary Ab (black). b. Left: Schematic of fluorescing beads in 
the channel above a pen containing an individual B cell indicates antigen-specific reactivity. Top right: False-color still image of positive wells with B cells 
secreting S2Pecto-reactive antibodies. reactive antibody diffusing out of a pen is visualized as a plume of fluorescence. Bottom right: False-color still image 
of positive wells with B cells secreting rBD-mFc-reactive antibodies. c. representative images of rBD-mFc reactive B cells from a single-B-cell secretion 
assay. d. Identification of mAbs with hACE2-blocking activity using single-cell functional screening. Left: Schematic illustrating detection of secreted Ab 
and hACE2 binding on an rBD-mFc-coated streptavidin bead. Ab binding was detected in one fluorescent channel, while hACE2 binding was detected 
in another fluorescent channel. The top panel illustrates an rBD-binding, non-blocking mAb, where the bead is positive for both Ab and hACE2 signals, 
while the bottom panel illustrates an rBD-binding mAb that competes with hACE2 for binding, where the bead is positive for only Ab signal. right: 
representative images of a B cell secreting non-blocking Abs (top) and a B cell secreting hACE2-blocking mAbs (bottom). Streptavidin beads are loaded 
into the same pens as B cells. The fluorescence of the streptavidin beads in the same pen as the B cell secreting hACE2-blocking Abs is reduced relative to 
adjacent wells, indicating hACE2-blocking activity.
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Extended Data Fig. 4 | Real-time cell analysis assay to screen for neutralization activity. a. Curves for fully neutralizing mAb (green) and partially 
neutralizing mAb (red) by monitoring of CPE in Vero-furin cells that were inoculated with SArS-CoV-2 and pre-incubated with the respective mAb. 
Uninfected cells (blue) and infected cells without antibody addition (grey) served as controls for intact monolayer and full CPE, respectively. Data 
represent a single well measurement for each mAb at the highest tested concentration, mean ± SD values of technical duplicates for the positive CPE 
control, and mean ± SD values of technical quadruplicates for the no-CPE controls. b. Example sensograms from individual wells of 384-well E-plate 
analysis showing rapid identification of SArS-CoV-2 neutralizing mAbs. Neutralization was assessed using micro-scale purified mAbs and each mAb was 
tested in four 5-fold dilutions as indicated. Plates were measured every 8–12 hrs for a total of 72 hrs as in (a).
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Extended Data Fig. 5 | Real-time cell analysis assay to quantify neutralization potency. Dose-response curves showing activity of neutralizing mAbs 
that were identified by rapid screening using the rTCA assay, as in Extended Data Fig. 4. Each mAb was tested in four sequential five-fold dilutions 
from micro-scale purified samples in which mAbs concentrations were not normalized but quantified. Neutralization was calculated as the percent 
of maximal cell index in control wells without virus minus cell index in control (virus-only) wells that exhibited maximal CPE at 40 to 48 hrs after 
applying virus-antibody mixture to the cells. a. representative neutralizing mAbs that fully prevented CPE at the lowest tested dilution (corresponding 
to the highest tested mAb concentration) are shown. IC50 values estimated from each curve are indicated. Curves for potently neutralizing mAbs 
(IC50 < 100 ng/mL) are shown in orange, from which mAbs COV2–2355 and COV2–2381 are genetically related. b. representative neutralizing mAbs that 
partially prevented CPE at the lowest tested dilution (corresponding to the highest tested mAb concentration) are shown.
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Extended Data Fig. 6 | Quantitative neutralization assays of VSV-SARS-CoV-2. Dose-response neutralization of VSV-SArS-CoV-2 by neutralizing mAbs. 
IC50 values are indicated for each mAb. Data shown are the mean of two technical replicates from a single experiment, and error bars denote the standard 
deviation for each point.
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided 
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) 
AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code
Data collection We used the 10X Genomics cellranger (version 2.1.1) [https://support.10xgenomics.com/single-cell-gene-expression/software/overview/
welcome] bioinformatics processing pipeline. We began by first running the cellranger mkfastq program to generate FASTQ files that 
were then fed into the cellranger vdj program to generate CSV and JSON files containing processed data. All processed heavy and light 
chain sequences were then reprocessed using our PyIR (version 1.0) [https://github.com/crowelab/PyIR] processing pipeline. PyIR is a 
Python wrapper that parses out VDJ assignment from IgBLAST [PMID: 23671333 ].
Data analysis We used a customized Python script, 10x-filter.py, for downstream selection of heavy-light pairs for expression and testing. The script 
begins by filtering out all ambiguous heavy and light chain pairings. It then bins all unique heavy chain somatic variants with the same V3J 
clonotype (i.e., V germline gene, J germline gene and CDR3 amino acid sequence). The heavy chain somatic variants are then rank- 
ordered within each V3J clonotype bin from most to least mutated. The user has the option to output only the most mutated sequence 
or least mutated sequence from each V3J clonotype bin for downstream expression and characterization. Code used for sequence 
processing for selecting sequences for synthesis and for analyses that appear in the paper is available at https://github.com/crowelab/
cov2-panel-scripts. 
 
For ELISAs binding data and neutralization assays, analyses of data were performed using Prism 8.0 (GraphPad Inc).  
 
For generation of structural schematics for Figure 3, PyMOL (Schrödinger) was used to visualize previously deposited cryo EM and crystal 
structures. 
 
For IgG quantification, data were analyzed using ForeCyt software version 6.2 (IntelliCyt Corp). 
 
For RTCA neutralization assays, sensograms were visualized and analyzed using RTCA HT software version 1.0.1 (ACEA Biosciences Inc). 
 
For VSV-SARS-CoV-2 neutralization assays, images were analyzed using the Multi Target Analysis Module of the InCell Analyzer 1000 
Workstation Software (GE Healthcare). GFP-positive cells were identified using the top hat segmentation method and counted within the 
2





InCell Workstation software. 
 
For negative-stain electron microscopy analysis, image processing was performed using the cryoSPARC software package. 
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. 
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
Data
Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: 
- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
The main data supporting the results in this study are available within the paper and Supplementary Information. The ImMunoGeneTics database is available from 
http://www.imgt.org/. The analysis pipeline PyIR (https://github.com/crowelab/PyIR) and the specific scripts used for sequence analysis (https://github.com/
crowelab/cov2-panel-scripts) are available. Structures deposited by other groups for the full-length spike trimer (6VYB) and the RBD–hACE2 complex (6M0J) that 
were used for visualization in this paper are publicly available (www.rcsb.org). Sequences for mAbs described in this study have been deposited at GenBank and are 
available under the following accession codes: MT665032 - MT665070, MT665419 - MT665457, MT665071 - MT665418, and MT665458 - MT665805. Datasets are 
available from the corresponding authors upon reasonable request.
Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences  Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size No sample-size calculations were performed. For mAb isolation, a large number of antibodies cloned and synthesized yielded mAbs targeting 
multiple epitopes on the spike glycoprotein, suggesting that the pandel described here represents a diverse repertoire from these donors. 
Details about research subjects groups are provided in Supplementary information. 
Data exclusions No data were excluded from the analysis
Replication Key experimental findings that include identification of SARS-CoV2-reactive and neutralizing human monoclonal antibodies were confirmed in 
two or more independent experiments. Initial neutralization screening results by the RTCA assay were confirmed using a VSV-SARS-CoV-2 
virus neutralization assay, and the neutralization activity of several of these mAbs was confirmed using a SARS-CoV-2 luciferase reporter virus 
in a BSL-3 neutralization assay. All mAbs that neutralized in the cell impedance assay showed neutralizing activity in subsequent neutralization 
assays.  
 
For antigen-specific staining of PBMCs from the human subjects studied, analytical flow cytometry was performed prior to initiating 
processing of the larger sample. The antigen specific frequencies we observed for a given donor sample were similar across multiple days and 
independent staining reactions. Following sorting, a small fraction of sorted cells was analyzed by analytical flow cytometry to verify the purity 
of the sorted population prior to initiating single cell sequencing or B cell stimulation or expansion.
Randomization Antibody sequences were randomly allocated to different 96 well plates for DNA synthesis and for the initial antibody expression and 
screening assays, with the end result that antibodies with highly similar sequences and phenotypes were present across plates and 
experimental replicates.
Blinding The initial antibody expression and screening for antigen reactivity and neutralization activity was done in a blinded fashion, as a given 
antibody sequence was not known to the investigator at time of analysis. Importantly, multiple mAbs discovered by independent workflows 
were closely related and some had identical amino acid sequences and exhibited similar phenotypes in both antigen binding and 
neutralization assays. For the mAb validation experiments, investigators were not blinded to the study groups. Quantitative data analysis and 
validation controls were used, minimizing the risk of introducing bias through the absence of blinding. 
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, 
system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
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Materials & experimental systems













Antibodies used B cell phenotyping flow cytometry antibodies included APC mouse anti-human CD19 (BioLegend clone HIB19 Cat# 982406, Lot 
B270238), FITC anti-human IgM (BioLegend clone MHM-88, Cat# 314506, Lot B218736), and FITC anti-human IgD (BioLegend 
clone IA6-2, Cat# 348206, lot B258195).  
Polyclonal goat anti-human IgG-HRP antibody (Southern Biotech Cat 2040-05, Lot B3919-XD29) was used for antigen binding 
ELISA assays.  
For FRNT assay, a previously described anti-SARS S-protein human antibody CR3022 (PMID: 32245784) was used as a primary 
antibody and the detection was performed using a goat anti-human IgG (γ-chain specific)-peroxidase antibody (Sigma-Aldrich, 
Cat# A6029).  
For antigen binding and hACE2 blocking screening assays on Berkeley Lights’ Beacon instrument, goat anti-human IgG (H+L) 
cross-adsorbed secondary antibody, Alexa Fluor 568 (ThermoFisher Scientific Cat# A-21090), and rat anti-FLAG Alexa Fluor 647 
antibody (BioLegend clone L5, Cat #637315, Lot B265929) were used. 
Validation All antibodies used in this study except anti-S human antibody CR3022 (PMID: 32245784) are commercially available. Antibodies 
used in a specific species or application have been appropriately validated by manufacturers and this information is provided on 
their website and information datasheets as follows: 
APC mouse anti-human CD19 (https://www.biolegend.com/en-us/products/apc-anti-human-cd19-antibody-14024); 
FITC anti-human IgM (https://www.biolegend.com/en-us/products/fitc-anti-human-igm-antibody-2880); 
FITC anti-human IgD (https://www.biolegend.com/en-gb/products/fitc-anti-human-igd-antibody-6683);  
Goat anti-human IgG-HRP (https://www.southernbiotech.com/?catno=2040-05&type=Polyclonal#&panel1-1&panel2-1); 
Goat anti-human IgG (γ-chain specific)-peroxidase antibody (https://www.sigmaaldrich.com/catalog/product/sigma/a6029?
lang=en&region=US).  
Goat anti-human IgG (H+L) cross-adsorbed secondary antibody, Alexa Fluor 568 (https://www.thermofisher.com/order/genome-
database/dataSheetPdf?producttype=antibody&productsubtype=antibody_secondary&productId=A-21090&version=105)   
Rat anti-FLAG Alexa Fluor 647 (https://www.biolegend.com/fr-ch/global-elements/pdf-popup/alexa-fluor-647-anti-dykddddk-
tag-14979?filename=Alexa%20Fluorreg%20647%20anti-DYKDDDDK%20Tag%20Antibody.pdf&pdfgen=true)   
Activity of newly discovered SARS-CoV-2-specific monoclonal antibodies are validated via multiple assays described in this paper. 
Eukaryotic cell lines
Policy information about cell lines
Cell line source(s) Vero E6 (CRL-1586, (American Type Culture Collection [ATCC}) 
Vero CCL81 (CCL-81, ATCC)  
HEK293T (CRL-3216 ATCC) 
Vero-furin cells were obtained from T. Pierson (NIH) and have been described previously (reference 2, Online Methods).  
Expi293F (ThermoFisher Scientific, A1452)  
ExpiCHO (ThermoFisher Scientific, A29127)  
Authentication None of the cell lines used were authenticated 





Policy information about studies involving human research participants
Population characteristics We studied five subjects in the United States, four with SARS-CoV2 exposure history and one healthy subject. Research subject 
demographics and SARS-CoV-2 exposure history are found in Supplemental Table 3.  
SARS-CoV-2-infected subjects: 
Subject 1: Male, 35 years old 
Subject 2: Female, 52 years old 
Subject 3: Male, 56 years old 
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Subject 4: Female, 56 years old 
Healthy control subject: 
Subject 5, Male, 58 years old 
Recruitment Samples were obtained after written informed consent was obtained by the Vanderbilt Clinical Trials Center. Participants were 
selected for inclusion in the study based on PCR-confirmed diagnosis with SARS-CoV-2 infection and having convalesced. There 
was no potential self-selection bias in recruiting patients. 
Ethics oversight The studies were approved by the Institutional Review Board of Vanderbilt University Medical Center




The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plots with outliers or pseudocolor plots.
A numerical value for number of cells or percentage (with statistics) is provided.
Methodology
Sample preparation The frequency of SARS-CoV-2 spike antigen-specific B cells was enumerated from B cells pre-enriched from fresh or frozen 
PBMCs. B cells were labeled using a soluble recombinant S2Pecto protein produced in our laboratory and commercially available 
receptor-binding domain (RBD)-mouse Fc-fusion recombinant protein (Sino Biological). Functionality of antigens was validated 
using a conventional ACE2 binding assay. Briefly, B cells were purified magnetically (STEMCELL Technologies) and stained with 
anti-CD19, -IgD, -IgM, phenotyping antibodies (BD Biosciences) and biotinylated S protein. 4ʹ,6-diamidino-2- phenylindole (DAPI) 
was used as a viability dye to discriminate dead cells. Antigen-labeled class-switched memory B cell-S complexes (CD19+IgM-IgD-
SARS-CoV2 S+DAPI-) were detected with phycoerythrin (PE)-labeled streptavidin conjugate and quantified using a SH800 cell 
sorter (Sony). After identification of the two subjects with the highest B cell response against S2Pecto protein, target-specific 
memory B cells were isolated by FACS using an SH800 cell sorter (from pooled PBMCs of these subjects, after labeling of B cells 
with biotinylated S protein. These details are also found in the Methods section.  
Instrument A SH800 cell sorter (Sony) was used for FACS and analytical flow cytometry studies
Software SH800 software and FlowJo version 10 (Tree Star Inc.). 
Cell population abundance Frequency of antigen-specific B cells ranged from 0.2 to approx. 1 % of class-switched memory B cells. Antigen specificity of 
sorted cells was validated in functional assays after production of recombinant antibodies, which included antigen binding and 
virus neutralization.
Gating strategy PBMCs were pre-enriched for B cells using magnetic negative selection with commercial (STEMCELL Technologies) kit. Extended 
Data Fig. 2 indicates gating strategy for sorting of antigen-labeled class switched B cells, that included staining with phenotyping 
anti-CD19, anti-IgM, and anti-IgD antibodies. Pre-enriched memory B cells were first gated by forward and side scatter. Dead 
cells were excluded using a viability dye (DAPI). Class-switched memory B cells were gated from this viable population as CD19
+,IgM-,IgD-. The gate for the antigen-specific subset was placed based on staining of B cells isolated from a non- immune healthy 
donor (no exposure history to SARS-CoV-2). Specificity of antigen labeling was validated in functional assays after production of 
recombinant antibodies, which included antigen binding and virus neutralization. 
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
